AI start-up deepmirror has been awarded a Phase 2 Sovereign AI grant as part of Innovate UK’s support for British businesses building world-leading AI technologies. The grant will fund deepmirror’s data acquisition strategy in which it selects the experiments most likely to improve its molecular… Read More
The latest issue of Drug Discovery World is out now. The DDW Summer 2026 issue examines the multi-compound approach to autism, the outlook for GLP-1 therapies and highlights drug discovery innovators and Investors – investment challenges and opportunities for drug developers. It also included features on: The importance of tech and collaboration for immunotherapies The… Read More
UK life sciences company Isomorphic Labs has announced it has raised $2.1 billion to scale its AI drug design engine. The company raised the capital in a Series B financing round, which Isomorphic Labs says will accelerate the company’s evolution from pioneering novel AI models to applying them… Read More
Biotechnology company Nuclera has partnered with leadXpro on structure-based drug design for complex membrane proteins. The collaboration will bring together Nuclera’s eProtein Discovery system with leadXpro’s AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic development. Membrane proteins remain some of the most valuable yet difficult to obtain drug targets. The proteins are notoriously challenging… Read More
Galux, a company using AI to drive drug design, has raised $29 million to support its protein therapeutics platform. The Series B financing round brought together existing investors, including InterVest, DAYLI Partners, and PATHWAY Investment, with new investors Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea… Read More
Space manufacturing could become a platform for scientific discovery and biomedical advancement, according to analytics company GlobalData. Analysis from GlobalData suggests environments in space are increasingly accessible, with pharmaceutical and biotech companies focusing on low-Earth orbit to explore new opportunities. This includes advancing drug development,… Read More
Join DDW and Curia on 14 October for a webinar on how X-ray crystallography can accelerate the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several… Read More
Join DDW and Curia on 14 October for a webinar on how X-ray crystallography can accelerate the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several… Read More
Don’t miss this webinar on how X-ray crystallography can accelerate the drug design process, hosted by DDW and supported by Curia. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several potent compounds that… Read More
In this webinar hosted by DDW, Curia shares its findings that protein X-ray crystallography is essential to accelerate the design process by providing a level of structural detail unmatched by computational methods. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding… Read More
Hosted by Drug Discovery World and supported by Curia, this free webinar explores the use of protein X-ray crystallography in accelerating the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying… Read More
Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier, looks at how artificial intelligence (AI) can improve the hit-to-lead process for small molecules. Early drug discovery takes an average of three-to-six years and accounts for 42% of total costs1 in the development of a new drug. It’s therefore no surprise that… Read More
Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes, as well as continued company growth… Read More
In a new scientific paper, AI-driven biotech Gero has demonstrated the feasibility of applying quantum computing to drug design and generative chemistry. The research, published in Scientific Reports, outlines how a hybrid quantum-classical machine-learning model was used to interface between classical and quantum computational devices with… Read More
Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies. Context Current approaches to optimise antibodies, even those that use machine learning, still… Read More
In a recent paper in the Journal of Chemical Information and Modeling, authors from the Cambridge Crystallographic Data Centre (CCDC), Exscientia, and Oxford University show how an automated process leveraging “ensemble hotspot maps” can identify key structural differences that contribute to the selectivity of a compound for one protein over… Read More
